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 Introduction 
 Cold atmospheric pressure plasma (CAP), an argon 
plasma at ambient temperatures and in tissue-tolerable 
doses, has become an interesting treatment option for dif-
ferent infectious as well as non-infectious diseases  [1, 2] . 
CAP has been investigated in the treatment of chronic 
wounds  [3, 4] , including chronic ulcers without  [5] and 
in combination with the antiseptic octenidine  [6] (which 
increased the efficacy of CAP due to its residual antimi-
crobial effect  [7] ), on skin graft donor wounds  [8] , for 
skin antisepsis  [9–12] , and for the inactivation of micro-
organisms embedded in biofilms  [13–17] .
 The biological effects of kINPen09 ® (neoplas GmbH, 
Greifswald, Germany), one of the best-described plasma 
sources for the application of CAP to surfaces, are main-
ly caused by reactive oxygen and nitrogen species in the 
plasma flow or by plasma contact with liquids or organic 
substances  [2, 9, 18, 19] .
 The antimicrobial activity of the kINPen09 ® has been 
investigated against a wide spectrum of microorganisms 
 [20–24] , and has demonstrated the ability to reduce the 
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 Abstract 
 Previous studies on the antimicrobial activity of cold atmo-
spheric pressure argon plasma showed varying effects 
against  mecA + or  mecA –  Staphylococcus aureus strains. This 
observation may have important clinical and epidemiologi-
cal implications. Here, the antibacterial activity of argon plas-
ma was investigated against 78 genetically different  S. au-
reus strains, stratified by  mecA ,  luk-P ,  agr1–4 , or the cell wall 
capsule polysaccharide types 5 and 8. kINPen09 ® served as 
the plasma source for all experiments. On agar plates,  mecA + 
 luk-P –  S. aureus strains showed a decreased susceptibility 
against plasma compared to other  S. aureus strains. This 
study underlines the high complexity of microbial defence 
against antimicrobial treatment and confirms a previously 
reported strain-dependent susceptibility of  S. aureus to plas-
ma treatment.  © 2016 S. Karger AG, Basel 
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 Table 1.  Overview on all investigated clinical S. aureus isolates (nasal carriage, blood culture, furunculosis, wound, lesion, pharyngeal 
or unknown origin) used in this study
Origin Deduced 
MLST-CC
Name mecA luk-P agr-type spa-type ID CP Tested
on agar
Tested on
biofilm
Nasal carriage CC5 SH 042-1 – – 2 t002 5 •
CC5 SH 093-1 – – 2 t002 5 •
CC5 sh08277 + – 2 t010 5 •
CC5 sh02636 + – 2 t151 5 •
CC7 SH 081-2 – – 1 t091 8 •
CC8 SH 010-1 – – 1 t008 5 •
CC8 T 169-1 – – 1 t711 5 •
CC12 SH 059-1 – – 2 t156 8 •
CC12 T 194-1 – – 2 t156 8 •
CC15 SH 027-1 – – 2 t084 8 •
CC15 SH 070-1 – – 2 t084 8 •
CC22 330756 + – 1 t608 5 •
CC22 SH 072-1 – – 1 t005 5 •
CC22 SH 073-1 – – 1 t005 5 •
CC22 sh12648 + – 1 t020 5 •
CC22 sh13413 + – 1 t032 5 •
CC22 sh18700 + – 1 t032 5 •
CC22 sh19108 + – 1 t020 5 •
CC22 sh19149 + – 1 t032 5 •
CC22 sh05385 + – 1 t608 5 •
CC22 SZ 255 – – 1 t005 5 • •
CC22 SZ 296 – – 1 t2816 5 •
CC25 SH 015-1 – – 1 t056 5 •
CC25 T 192-1 – – 1 t078 5 •
CC30 SH 039-1 – – 3 t012 8 •
CC30 SH 079-1 – – 3 t122 8 •
CC30 sh26625 – – 3 t122 8 •
CC45 SH 001-2 – – 1 t302 8 •
CC45 SH 013-2 – – 1 t302 8 •
CC45 sh16309 + – 1 t004 8 •
CC45 SZ 148 + – 1 t1078 8 • •
CC59 SZ 179 + + 1 t437 8 •
CC121 SZ 034 – – 4 t435 8 •
CC121 SZ 275 – – 4 t4495 8 • •
CC395 T 110-1 – – 1 t1651 8 •
CC395 T 191-1 – – 1 t1645 8 •
Blood culture CC7 BK 091 – – 1 t091 8 •
CC7 BK 099 – – 1 t091 8 •
CC8 98-00406 + – 1 t051 5 • •
CC8 BK 010 – – 1 t008 5 •
CC8 BK 077 – – 1 t190 5 • •
CC12 BK 050 – – 2 t160 8 •
CC12 BK 058 – – 2 t156 8 •
CC15 BK 017 – – 2 t084 8 •
CC15 BK 040 – – 2 t094 8 •
CC22 BK 005 – – 1 t1120 5 •
CC22 BK 090 – – 1 t1665 5 •
CC25 BK 015 – – 1 t056 5 •
CC25 BK 075 – – 1 t078 5 •
CC30 BK 002 – – 3 t012 8 •
CC30 BK 080 – – 3 t021 8 • •
CC45 BK 020 – – 1 t015 8 •
CC45 BK 051 – – 1 t230 8 •
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number of microorganisms, such as methicillin-sensitive 
 Staphylococcus aureus (MSSA) and methicillin-resistant 
 S. aureus strains (MRSA, carrying the  mecA gene)  [25–
28] . However, testing the efficacy of CAP on culture 
plates or biofilm showed varying effects, and details of the 
results pertaining to the application of plasma against  S. 
aureus strains with or without the presence of the  mecA 
gene indicate a possible increased tolerability of  mecA + 
 strains  [25, 27, 29] . This observation may have important 
clinical and epidemiological implications, since the ap-
plication of CAP on chronic, multi-strain colonized 
wounds may result in the selection of antibiotic-resistant 
strains or bacterial strains with particular virulence fac-
tors. Furthermore, if this effect were dose dependent, the 
plasma dosage would need to be adjusted to achieve the 
necessary antimicrobial effect without selecting specific 
strains.
 Based on the above, the aim of the present study was 
to investigate the antibacterial activity of CAP on 78 ge-
netically different  S. aureus strains, including MSSA and 
MRSA with and without Panton-Valentine leucocidin 
( luk-P ), different  agr types, and capsule polysaccharide 
types on culture plates or in biofilm.
 Methods 
 Test Organisms 
 A total of 78 genetically different  S. aureus strains were inves-
tigated in this study. Thereof, 19  S. aureus strains were obtained 
from the nasal cavity of asymptomatic carriers from Northern 
Germany (T, SH strains)  [30] , 6 strains were obtained from the 
nasal cavity of asymptomatic carriers from Szczecin, Poland (SZ 
strains)  [31] , 20 strains were obtained from patients from the Uni-
versity Hospital of Greifswald (BK strains)  [30] , and 17 strains 
were obtained from patients with furunculosis from a mature fu-
Origin Deduced 
MLST-CC
Name mecA luk-P agr-type spa-type ID CP Tested
on agar
Tested on
biofilm
CC121 BK 036 – – 4 t272 8 •
CC121 BK 078 – – 1 t916 8 •
CC395 BK 066 – – 1 t1362 8 •
CC395 BK 084 – – 1 t1645 8 •
Furuncle CC1 H 3672 – – 3 t177 8 •
CC1 H 5613 – – 3 t127 8 •
CC5 H 7176 – + 2 t002 5 •
CC8 05-01825 + + 1 t008 5 • •
CC8 H 0757 – + 1 t068 5 •
CC8 H 3163 – + 1 t068 5 •
CC15 H 6110 – – 2 t084 8 •
CC22 H 6754 – + 1 t005 5 • •
CC22 H 9418 – + 1 t1132 5 •
CC30 H 0678 – + 3 t037 8 • •
CC30 H 2966 – + 3 t318 8 •
CC45 H 3442 – – 1 t116 8 • •
CC45 H 4764 – – 1 t015 8 •
CC59 H 5391 + + 1 t437 8 •
CC121 H 0070 – + 4 t284 8 • •
CC121 H 4053 – + 4 t435 8 •
CC121 H 5313 – + 4 t159 8 •
CC121 H 5751 – + 4 t272 8 •
Wound CC5 ATCC 29213 – – 2 t002 5 •
Pharyngeal CC45 SZ 16315 + – 1 t004 8 •
Lesion ST464 ATCC 6538 – – 1 t3297 - • •
MLST-CC = Multi-locus sequence typing – clonal complex; CP = capsule polysaccharide.
Table 1 (continued)
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runcle during the acute phase of skin infection or by a surgeon 
during abscess incision, as described in Masiuk et al.  [31] (H 
strains). All these strains were analysed for their clonal relationship 
( spa typing), and genotyped (multiplex PCR) for a range of viru-
lence factors, methicillin resistance  (mecA) and  luk-PV genes  [30, 
31] . Based on this detailed characterization, we randomly selected 
strains from each clinical cohort (nasal colonization, blood cul-
ture, furunculosis) for subsequent analyses, representing the whole 
spectrum of virulence factors ( table 1 ).
 Moreover, we included 2 ATCC (American Type Culture Col-
lection) reference MSSA strains (ATCC 6538 and ATCC 29213), 
as well as 12 MRSA isolates of healthy carriers, obtained from the 
currently ongoing Study of Health in Pomerania (SHIP study), a 
large-scale, comprehensive population-based study in Western 
Pomerania ( table 1 )  [32] . Out of these 12 MRSA strains, 1 isolate 
originated from a throat swab (sh16315), while the other 11 iso-
lates were obtained from the nasal cavity.
 Two isolates, strain 05-01825 ( mecA + ,  luk-P + ) and strain 98-
00406 ( mecA + ,  luk-P – ), were obtained from the Robert Koch Insti-
tute, Wernigerode, Germany ( table 1 ) and were analysed by Strom-
menger et al.  [33] . Screening of the susceptibility of all  S. aureus 
strains was carried out on Columbia blood agar plates (BD, Hei-
delberg, Germany). Based on different  spa clonal complex clusters 
(CC8, CC22, CC30, CC45, CC121) and the prevalence of  mecA and 
 luk-P within these clusters, 12 selected strains were used for ex-
periments on biofilms ( table 1 ). The capsular polysaccharides were 
deduced in accordance with the multi-locus sequence typing clus-
ter of each strain  [34–37] .
 Bacterial Cultivation and Preparation for Plasma Application 
 The test organisms used for stock- and subculture were stored 
at –70  °  C attached onto glass beads. For cultivation, the test organ-
isms were maintained on Columbia blood agar (BD) for 24 h at 
37  °  C. The stock cultures were stored at 4  °  C for maximal 4 weeks 
to prepare the subcultures. The subcultures were prepared on the 
day before the experiment. A loopful of grown bacteria was diluted 
in 5 ml of 0.9% (v/w) PBS solution (PAA Laboratories, Cölbe, Ger-
many). This suspension corresponded to an initial concentration 
of 10 8 colony-forming units (CFU)/ml. After dispersion by whirl-
ing for 1 min (Vortex-Genie 2; Scientific Industries, New York, 
N.Y., USA), the suspension was serially diluted in sterile PBS. For 
the experiments, 10 4 CFU/ml for plasma application and 10 2 CFU/
ml for the treatment with argon gas (gas control) and the control 
(untreated test organisms) were used. The used dilutions were de-
termined in pre-tests to obtain countable quantities of CFU after 
treatment. For standardized spreading of the bacteria on agar 
plates 50 μl of the corresponding suspension were applied by a spi-
ral plater (Meintrup DWS, Lähden-Holte, Germany). The inocu-
lated plates were incubated for 20 min at room temperature to get 
homogenously dry surfaces.
 Plasma Treatment 
 A cold atmospheric pressure argon plasma pen (kINPen09 ® ; 
neoplas GmbH), using argon (99.995% pure) as carrier gas with a 
gas flow rate of 5 slm (standard litres/min), was used as the plasma 
source to generate spatial afterglow plasma. The gas flow was con-
trolled by a mass flow controller (MKS Instruments, Munich, Ger-
many). The plasma pen frequency was set at 1.1 MHz with a max-
imum input DC power of 3.5 W to the hand-held unit  [38] . At this 
input power a mean heat output of about 300 mW is generated on 
a
b
c
 Fig. 1. Experimental set-up for the plasma application. The plasma 
pen is fixed above the blood agar plate ( a ) with, respectively, 10 2 
or 10 4 CFU of  S. aureus in a computer-controlled plotter ( b ).
 c Movement pattern for the plasma jet over the agar plate surface. 
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the surface  [38] . The generated plasma jet was directed at the treat-
ed surface open to the indoor air during treatment.
 For all experiments, the plasma pen was fixed in a computer-
controlled x/y/z table (modified EDX-20; Roland DG, Westerlo, 
Belgium;  fig.  1 a). Each prepared agar plate was positioned at a 
distance of 7 mm below the nozzle of the pen ( fig. 1 b). Two quar-
ters of the plate were treated in a curved meander at a speed of 10 
mm/s 10 times, resulting in a total treatment time of approximate-
ly 6 s per point. The distance between the meandering lines was
3 mm ( fig. 1 c). The temperature on the surface during treatment 
did not exceed 41   °   C. Each strain and treatment type, including 
the gas (without plasma) and untreated controls, was performed 
twice. After treatment, the agar plates were incubated for 24 h at 
37  °  C. Treatment of the polystyrene-grown biofilms of the select-
ed 12 strains was carried out at least 8 times for the control, 10 
times for plasma treatment and 3 times the gas control (gas flow 
without plasma), as described previously by Matthes et al.  [39] . 
From the 78 strains screened, a sample of 12 strains was selected 
for biofilm tests to represent different clonal complexes, capsular 
polysaccharide types (5 and 8), and variable presence of  mecA and 
 luk-P .
 Statistical Analyses 
 CFU were calculated using the Spiral ® counting grid according 
to the manufacturer’s instructions (Meintrup DWS) and were ex-
pressed in log 10 (CFU/ml). CFU of the treated plates were com-
pared with the median of the non-treated control plates of each 
test. The log 10 reduction factor (RF log 10 ) was defined by the for-
mula:
 RF log 10 = log 10 (mc) – log 10 (vs)
 where ‘mc’ described the median of the (untreated) control values 
of each test organism and ‘vs’ the single value of the treated sample 
(plasma or gas alone). All tests on Columbia agar plates were con-
ducted in duplicate, and all tests on biofilm were repeated 10-fold. 
The standard deviations and p values (α = 0.05) were calculated for 
the RFs. Statistical differences were analysed using the Kruskal-
Wallis test, followed by Dunn’s multiple comparison test or the 
Mann-Whitney U test to analyse two groups with each other, such 
as  mecA + versus mecA – and variants of  luk-P – versus  luk-P + , or 
capsular polysaccharide 5 versus capsular polysaccharide 8 (Prism; 
GraphPad, La Jolla, Calif., USA). 
 Results 
 The average reduction of CFU for  S. aureus strains on 
Columbia blood agar after plasma treatment was 2.59 ± 
0.25 RF log 10 . Gas treatment (without plasma) achieved a 
non-significant reduction of RF log 10 0.28 ± 0.16 and was 
significantly less effective compared to plasma treatment. 
The  mecA + (all)  S. aureus strains were significantly less 
susceptible to CAP than the  mecA – (all) strains, with a dif-
ference of 0.2 log 10 (p < 0.01). Additionally, strains of 
 mecA + (all),  mecA +  luk-P – , and  mecA – luk-P – strains 
showed a statistically significantly lower susceptibility 
against CAP compared to  mecA –  luk-P + strains, with a 
difference of 0.4 or 0.2 CFU/ml (p < 0.05;  fig. 2 ).
 After a comparison of the  S. aureus strains on the basis 
of the  agr type, the  agr3 group was statistically more sus-
ceptible to CAP than the  agr1 and  agr2 groups (p < 0.05; 
 fig. 3 ). In contrast, grouping the isolates by the capsular 
polysaccharide types 5 and 8, which are linked to  S. au-
reus lineages, did not show any statistically significant dif-
ference after plasma treatment on agar plates ( fig. 3 ). No 
significant difference was shown (p > 0.05) between the 
clonal complex clusters (CC5, CC8, CC12, CC15, CC22, 
CC25, CC30, CC45, CC121, CC395).
mecA–
(all)
(n = 62)
mecA+
(all)
(n = 16)
*
luk-P–
(all)
(n = 14)
luk-P+
(all)
(n = 64)
*
mecA–
(luk-P–)
(n = 51)
mecA–
(luk-P+)
(n = 11)
*
mecA+
(luk-P–)
(n = 13)
mecA+
(luk-P+)
(n = 3)
*
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
RF
 Fig. 2. Impact of  mecA and  luk-P on the re-
duction of CFU/ml in log 10 of 78 different 
 S. aureus strains on sheep blood agar af-
ter plasma treatment. The  mecA +/– and
 luk-P +/– subgroups were compared. Box-
plot graph depict the median, 25th percen-
tile, minimum and maximum, and number 
of values (respective number of strains) of 
each group. Assays were performed in du-
plicate. The asterisks indicate statistically 
significant difference between the respec-
tive groups. 
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 Plasma treatment of the 12 selected  S. aureus strains 
embedded in biofilm showed an average reduction of RF 
log 10 1.86 ± 0.22. Gas treatment alone resulted in an aver-
age RF log 10 of 0.77 ± 0.25 and was not significantly dif-
ferent from the respective controls (p > 0.05). Here, the 
average median of the biofilm controls was 8.36 ± 0.23 
log 10 CFU/ml. Within this strain cohort, we did not ob-
serve a difference in susceptibility to gas treatment be-
tween  mecA – or  mecA + strains,  luk-P + and  luk-P – strains, 
the  agr group, or the group of the capsular polysaccharide 
types 5 and 8 ( table  2 ). No significant difference was 
shown (p > 0.05) between the clonal complex clusters 
(CC8, CC30, CC45, CC88, CC121). Detailed results for 
both test conditions are summarized in  table 2 . The RF 
values of the agar- and biofilm-grown  S. aureus did not 
correlate, and no segregation of the  mecA ,  luk-P ,  agr , and 
capsular polysaccharide subgroups was observed (data 
not shown).
 Discussion 
 Different researchers have investigated the effect of 
‘cold’ atmospheric pressure plasma on drug-resistant 
bacteria such as MRSA in planktonic conditions, adhered 
on surfaces, or embedded in biofilm  [25, 26, 28, 29, 40, 
41] . Some of these studies showed differences in the sus-
ceptibility of MRSA and MSSA strains to plasma treat-
ment for the planktonic form and after biofilm cultiva-
tion, with an increased survival rate of approximately 6% 
after treatment for 2 min  [27] , and from 5 up to 70% after 
treatment for 3 min on agar plates  [24, 25] . Other authors 
reported an increased susceptibility of 1 MRSA and 1 
MSSA strain compared to 2 MRSA strains (USA300 and 
USA400) in planktonic conditions  [29] . However, em-
bedded in biofilm, opposite results were observed. The 
different analysis methods used in the study conducted 
by Joshi et al.  [29] complicate a direct comparison be-
tween agar- and biofilm-treated strains, yet indicate that 
the different results may be caused by variations in the 
bacterial environment and the analysis method used.
agr1
(n = 47)
agr2
(n = 15)
agr3
(n = 9)
agr4
(n = 7)
*
CP 5
(n = 33)
CP 8
(n = 44)
*
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
RF
 Fig. 3. Impact of  agr and type of capsular polysaccharide (CP) on 
the reduction of CFU/ml in log 10 of 78 different  S. aureus strains 
on sheep blood agar after plasma treatment. The  agr1–4 and cap-
sular polysaccharide subgroups were compared. Boxplot graph de-
picting the median, 25% percentile, minimum and maximum, and 
number of values (respective number of strains) of each group. 
Assays were performed in duplicate. The asterisks indicate statisti-
cally significant difference between the respective groups. 
 Table 2.  Average RF (RF log10) of tested S. aureus strains after ar-
gon plasma treatment on Columbia agar plates (n = 78) and bio-
films (n = 12)
Genetic
background
Test organisms after plasma treatment
agar plates  biofilms
n RF±SD  n RF±SD
mecA– (all) 62 2.67 ± 0.27a 9 1.77 ± 0.24
mecA+ (all) 16 2.41 ± 0.23b 3 1.99 ± 0.20
luk-P– (all) 64 2.62 ± 0.28c 8 1.83 ± 0.20
luk-P+ (all) 14 2.78 ± 0.17 4 1.87 ± 0.29
mecA– (luk-P–) 51 2.65 ± 0.28b 6 1.83 ± 0.20
mecA– (luk-P+) 11 2.81 ± 0.17 3 1.75 ± 0.35
mecA+ (luk-P–) 13 2.33 ± 0.24b 2 1.90 ± 0.27
mecA+ (luk-P+) 3 2.65 ± 0.12 1 1.99
agr1 47 2.64 ± 0.27 8 1.94 ± 0.24
agr2 15 2.57 ± 0.23
agr3 9 2.83 ± 0.23d 2 1.63 ± 0.00
agr4 7 2.60 ± 0.25 2 1.85 ± 0.15
CP 5 33 2.60 ± 0.28 5 1.99 ± 0.27
CP 8 44 2.67 ± 0.25 6 1.73 ± 0.18
 SD = Standard deviation; CP = capsule polysaccharide.
a Significantly different from mecA+ (all) on agar plates. b Sig-
nificantly different from mecA– (luk-P+) on agar plates. c Signifi-
cantly different from luk-P+ (all) on agar plates. d Significantly dif-
ferent from the agr1, agr2 group, and all luk-P– groups on agar 
plates.
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 Our study confirms previously reported strain-depen-
dent variances in the susceptibility of  S. aureus against 
CAP. Consistent with observations by the other authors, 
mecA +  luk-P –  S. aureus strains showed a decreased sus-
ceptibility against CAP when grown on agar plates. In 
biofilms, however, no significant difference could be de-
termined for all investigated factors. This may be due to 
the limited cohort size used in our study or may reflect 
the effect of the biofilm form, which outnumbers the ef-
fect of variances between strains.
 One reported explanation for the observations after  S. 
aureus treatment on agar plates could be the differences 
in the general stress response and membrane lipid and/or 
protein composition  [27] . It is also known that the cell 
wall structure of microorganisms influences the diffusion 
of reactive oxygen species and therefore the antimicro-
bial efficacy of plasma  [42] . Actually, our results demon-
strate no statistical difference between the genetic back-
ground in producing capsule polysaccharide type 5 or 8 
for  S. aureus on agar plates or in biofilm. This suggests 
that the capsular polysaccharide type does not have an 
influence on the diffusion of plasma compounds through 
the cell wall and on the antimicrobial reactivity of CAP, 
and underpins that differences shown by various micro-
bial species could be mainly caused by the cell wall thick-
ness  [42] .
 Besides the oxidation processes of polysaccharides and 
lipids of the bacterial cell wall and membrane by reactive 
oxygen plasma compounds  [28, 42–44] , plasma can in-
duce a general stress response to the reactive products of 
the air-liquid-substrate interaction of plasma  [45] . Hence, 
the stress response towards plasma could be influenced 
by the different genetic backgrounds, resulting in differ-
ent metabolic activities or differences in cell wall struc-
ture depending on growth on agar or in a biofilm.
 However, it is also known that the acquisition of mo-
bile genetic elements encoding additional resistances or 
virulence factors could decrease the proliferation rate, fit-
ness, and survival in the environment  [46–48] . In our 
study, 3 different pathogenic markers were used to com-
pare their influence on the antibacterial effect of CAP. 
The phage-mediated virulence gene  luk-PV can express 
the pore-forming toxin Panton-Valentine leucocidin, 
which is associated with furunculosis and fulminant 
staphylococcal pneumonia  [49] . The expression of the 
chromosomal cassette-encoded  mecA leads to methicil-
lin-resistant pathogens  [50] . The global regulator gene 
 (agr) regulates the expression of different virulence genes; 
it is involved in the expression of different capsular poly-
saccharides, capsular proteins and biofilm development 
 [50–53] , and can influence the pathogenesis of infections 
 [54] .
 Reduced susceptibility against CAP of  mecA + strains 
was enhanced by the absence of  luk-P ( luk-P – ). The same 
influence of  luk-P was also observed by the MSSA strains. 
Here, the ability for the expression of  mecA seems to pro-
tect against the influence of CAP, whereas  luk-P or  agr3 
increase the sensitization against CAP. These results 
show that virulence and resistance genes can influence 
tolerability against plasma treatment. Even though the 
statistically significant differences of determined CFU 
show the complexity of the cell responses by CAP, they 
are microbiologically negligibly low and would not be rel-
evant in clinical use.
 Our study is limited by a number of factors. First, a 
selection bias may have occurred as we used clinical iso-
lates which had been collected during previous, ethics 
committee-approved studies. Second, although we tried 
to select subsets of strains for subanalysis based on their 
genetic/virulence profile, a matched-pair analysis was not 
possible because of the heterogeneity of the test material. 
This eventually also led to low numbers of isolates (e.g. in 
the  mecA +  luk-P + group).
 Our results indicate the influence of the genetic back-
ground on the antimicrobial effectiveness of plasma, 
which may be influenced by the variable expression of 
these genes in the different clinical isolates. The gene ex-
pression can vary dramatically under in vitro and in vivo 
conditions  [47, 55] .
 Conclusion 
 In conclusion, our results underline the high complex-
ity of microbial defence against antimicrobial treatment. 
Differences in the achieved reductions after the applica-
tion of CAP were observed. The clinical relevance of these 
observations remains unclear and may warrant further 
research, since the role of distinct genetic characteristics 
may have an impact on the selection and virulence of mi-
croorganisms under habitat conditions.
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